A really great article-- "Merkel has never spoken publicly about why she left science, but perhaps because it never really left her. Scientific thinking... remains integral to Merkel’s daily decision-making process" #WomenInScience bit.ly/350vflA

healio.com/news/hematolog…

Imagine Donald J. Trump, Joe Biden, Marco Rubio and Ted Cruz all in school with this gutsy and inspirational young man. Trump is the guy who would have bullied him. Rubio is the guy who would have looked away and Biden is the guy who would have knocked the bully on his ass. 1/2

Reviewers: if you are assigned a manuscript that is well written and data are clear, can we agree to say no changes needed? It seems many suggest unnecessary changes just to feel they are a good reviewer. This is damaging to students, postdocs and PIs 😡 Academic Chatter™

Charu Aggarwal, MD, MPH, FASCO ASCO Conquer Cancer, the ASCO Foundation Penn Medicine - Abramson Cancer Center Lynn Schuchter Eric J. Small, MD, FASCO Clifford Hudis Sandra Neelima Denduluri Aparna Raj Parikh Elizabeth Plimack MD Christina Annunziata Enrique Soto Nina Shah Love this!!

Study Led by Nilam Mangalmurti Finds Red Blood Cells Play Much Larger Role in Immune System Through Discovery of DNA-Binding Capability pennmedicine.org/news/news-rele…

Truly a multi-disciplinary effort with Drs. Jeff Thompson and Erica L. Carpenter, MBA, PhD in launching and completing our #RANGER study that showed that early plasma Bx can reduce time to treat! #LCSM IASLC PER Christian Rolfo Benjamin Levy @DrSteveMartin

International Society of Liquid Biopsy In the Spotlight: "Cell-free DNA analysis in current cancer clinical trials: a review". nature.com/articles/s4141…. Christian Rolfo M JOSE SERRANO Lab (LB&Cancer Interception group) Umberto Malapelle David Gandara ELO @MCristofanill

Drs. Jeffrey Thompson, Charu Aggarwal, MD, MPH, FASCO & Erica L. Carpenter, MBA, PhD led a non-small cell lung cancer #NSCLC patient study, performing liquid & diagnostic biopsies simultaneously. Results showed a decrease in time-to-treat vs usual care. Read more in JTO & JTO CRR: spr.ly/6010K98Jo.

The free & virtual BLOODPAC Summit will be here soon! Join the discussion on Thurs 3/31 2-4:30 pm ET, topics included: the state of liquid biopsy science, accessibility, & regulatory challenges. Visit bloodpac.org to find out more about the day. #cancer #liquidbiopsy

A comprehensive review of translational advances in #PancreaticCancer therapy💊in Nature Cancer. #PancreaticCancer is an aggressive cancer normally detected at advanced stages reducing treatment options with limited responses💉. A must read #OpenAccess!👀 nature.com/articles/s4301…

So proud to co-lead this study with Dr Mamtani and collaborate with Dr Hubbard and (soon to be Dr) Nimgaonkar.

Access to standard treatments in advanced bladder cancer remains challenging.  Our study, led by Vivek Nimgaonkar shows under utilization of FGFR testing & erdafitinib tx in practice Flatiron Health Bladder Cancer Advocacy Network Rebecca Hubbard Erica L. Carpenter, MBA, PhD jamanetwork.com/journals/jamao…

Kicking us off with a #HotTopic - applications of Liquid Biopsy Across multiple tumor types ⁦ ✨LiquidBx is changing management ✨Future applications- earlier detection, MRD assessment & monitoring ⁦Erica L. Carpenter, MBA, PhD⁩ ⁦@PennPrecisMed⁩ ⁦Penn Medicine - Abramson Cancer Center⁩

BREAKING: Sian Leah Beilock, the current president of Barnard College, will serve as Dartmouth College's next president. As the first woman named to this role in the College's history, she will assume office next July. ow.ly/Ugfq50K1gTB

Excited to share data on pembro + delayed Jaki (itacitinib) in 1L PDL1 high NSCLC. ORR @ 12 weeks 62% + interesting response patterns after Jaki. Come say hi today at the poster session! #WCLC22 Penn Medicine - Abramson Cancer Center Charu Aggarwal, MD, MPH, FASCO Corey Langer Joshua Bauml, MD IASLC E. John Wherry Andy Minn

Hillary Andrews, PhD JCO Precision Oncology Congrats to you, Erica L. Carpenter, MBA, PhD and team!

Thank you Hillary Clinton ❤️

So proud to have worked with Steve Bagley on this review of cfDNA in the setting of gliomas.